TAE Life Sciences Welcomes Dr. Deepak "Dee" Khuntia to Its Board of Directors
IRVINE, Calif., April 17, 2024 /PRNewswire/ -- TAE Life Sciences, a pioneer in advancing Boron Neutron Capture Therapy (BNCT) for cancer treatment, proudly announces the appointment of Dr. Deepak "Dee" Khuntia, M.D., FASTRO, to its esteemed Board of Directors. Dr. Khuntia brings unparalleled expertise and invaluable insights to the board, further strengthening TAE Life Sciences' position as a pioneer in the field of radiation oncology.
- As an authority in radiation oncology, Dr. Khuntia joining the board of directors validates BNCT and the work TAE Life Sciences is doing to make it a mainstay of modern cancer care
IRVINE, Calif., April 17, 2024 /PRNewswire/ -- TAE Life Sciences , a pioneer in advancing Boron Neutron Capture Therapy (BNCT) for cancer treatment, proudly announces the appointment of Dr. Deepak "Dee" Khuntia, M.D., FASTRO, to its esteemed Board of Directors. - Dr. Khuntia brings unparalleled expertise and invaluable insights to the board, further strengthening TAE Life Sciences' position as a pioneer in the field of radiation oncology.
- Dr. Khuntia expressed his excitement about joining TAE Life Sciences' board, stating, "I believe in the promising future of Boron Neutron Capture Therapy (BNCT) and its potential to transform the landscape of radiation oncology.
- For more information about TAE Life Sciences, Alphabeam, and the company's proprietary boronated BNCT drugs, please visit www.taelifesciences.com .